LYMPHOMA HUB CONTINUES ITS FOCUS ON RAISING THE LEVELS OF GLOBAL KNOWLEDGE OF LYMPHOMA THROUGHOUT Q2 2022

Press release: Available for immediate release

The Lymphoma Hub, run by Scientific Education Support in partnership with the European Lymphoma Institute, is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in lymphoma. By attending two key conferences this quarter, the Lymphoma Hub has ensured that the lymphoma community have received the latest news and insights in lymphoma treatment and research.

In June, the Lymphoma Hub virtually attended the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and provided live social media coverage as well as expert interviews on the latest research in cancer care. Later that month, we also attended the European Hematology Association (EHA) 2022 Congress and provided updates on cutting-edge evidence-based approaches to diagnosis and treatment, highly anticipated clinical and translational research data, as well as the latest innovative techniques, diagnostic tools, and risk-assessment strategies for lymphoma. Our coverage of these key congresses contributed to over 130,000 impressions on our social channels and over 16,500 website users this quarter.

The Lymphoma Hub also released three visual abstracts this quarter, summarizing key data from the phase I trial ELM-1, evaluating odronextamab in patients with CD20+ B-cell malignancies, safety, efficacy and pharmacokinetics of mosunetuzumab in non-Hodgkin lymphoma, and resource-stratified guidelines for the management of classical Hodgkin lymphoma.

Reviewing the Lymphoma Hub’s activity this quarter, Ellen Jenner, Scientific Team Lead, Scientific Education Support, said:

“This quarter has been an especially busy period for the Lymphoma Hub. As part of our commitment to continuously enhance the hub’s user experience, we have recently introduced a new drug and trial updates section on the Lymphoma Hub, which provides users with the most recent regulatory news for their area of interest. This new functionality, which imports all updates directly from the hub’s Twitter account, means that all drug and trial updates can be easily viewed and searched for in a single location.

“We have recently developed an exciting innovation on the hub which provides users with all of our Twitter congress coverage in one location. By attending key congresses such as ASCO and EHA, we are providing extensive coverage and education to those who cannot attend and ensuring that they are aware of educational messages and vital updates in lymphoma and CLL.”

Activity such as this would not be possible without our supporters. We would like to take this opportunity to express our gratitude to our existing supporters—Bristol Myers Squibb, Incyte, Roche, Pharmacyclics, BeiGene, ADC Therapeutics, Genentech, Lilly, Epizyme, AstraZeneca, and Daiichi-Sankyo. We would also like to thank our steering committee for their continued guidance.

ENDS

For more information on the Lymphoma Hub, please visit lymphomahub.com.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.

NOTES TO EDITOR

About lymphoma

Lymphoma is described as the development of neoplastic cellular growth—cancer—in the lymphatic system. Lymphomas are divided into two major categories: Hodgkin and non-Hodgkin lymphomas, where the latter is more common.

About the Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge of lymphoma and CLL through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the Lymphoma Hub supports HCPs worldwide.

Founded in partnership with the European Lymphoma Institute (ELI) in 2014, the Lymphoma Hub is guided by an international steering committee of experts in the field of lymphoma and CLL. The steering committee meet regularly to discuss the performance of the Lymphoma Hub and to devise action plans on how best to support the lymphoma community and address any unmet educational needs.

Lymphoma Hub supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

• Bristol Myers Squibb
• BeiGene
• Daiichi-Sankyo
• AstraZeneca

• Lilly
• Incyte
• Roche
• Genentech

• ADC Therapeutics
• Epizyme
• Pharmacyclics

If you are interested in becoming a Lymphoma Hub supporter, please contact secretariat@scientificeducationsupport.com.

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, MDS Hub, MPN Hub, and Multiple Myeloma Hub.

About The European Lymphoma Institute (ELI)

Lymphoma, the sixth cancer worldwide in terms of incidence, is a complex disease. ELI, The European Lymphoma Institute, regroups top European specialists in the field of lymphoma within a net dedicated to research, training and education. To date, thirteen European academic research groups have come together in an effort to define strategies to analyze and characterize this cancer, common diagnostic procedures and therapeutic standards as well as to facilitate clinical and fundamental research at the European level.